Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study to Evaluate the Safety and Efficacy of Peptide Receptor Radionuclide Therapy With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

NCT06081322 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06081322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06081322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study to Evaluate the Safety and Efficacy of Peptide Receptor Radionuclide Therapy With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
September 1, 2023
Completion date
June 30, 2025
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer and cholangiocarcinoma